Company: PFSA
Filing Date: 2025-10-29
Form Type: 424B3
Source: 0001213900-25-103174
Chunk: 306

Company: Profusa, Inc.
Filing Date: 2025-10-29
Form: 424B3
Chunk 306
---
CODM”) is its Chief Executive Officer, Ben Hwang, who reviews financial
information presented on a consolidated net loss basis as reported on the consolidated statement of operations in order to make decisions
about allocating resources and assessing performance for the entire Company. The CODM also utilizes the Company’s long-range plan,
which includes product development roadmaps and long-range financial models, as a key input to resource allocation. The CODM function
approves of key operating and strategic decisions. The CODM function views the Company’s operations and manages its business on
a consolidated basis and as a single reportable operating segment. The CODM function is regularly provided with the following significant
segment expenses. Significant expenses include research and development and general and administrative expenses, which are each separately
presented in the Company’s Consolidated Statements of Operations. The CODM reviews significant expenses within both the research
and development and the general and administrative categories. Other segment items within net loss include interest income, interest expense
and loss on change in fair value of related party loan. See the consolidated financial statements for other financial information regarding
the Company’s operating segment.

<div align='center'>F-28

PROFUSA, INC. AND SUBSIDIARY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</div>

Note 14 — Segments (cont.)

|                                                                                                                                       |     | Year Ended   
 December 31, |   2024 |   |     |   |    2023 |   |
|:--------------------------------------------------------------------------------------------------------------------------------------|:----|:-------------|-------:|:--|:----|:--|--------:|:--|
| Government grant revenue                                                                                                              |     | $            |    100 |   |     | $ |      45 |   |
| Operating expenses:                                                                                                                   |     |              |        |   |     |   |         |   |
| Research personnel compensation costs, including stock-based compensation                                                             |     |              |  1,350 |   |     |   |   1,641 |   |
| CRO and regulatory costs                                                                                                              |     |              |     36 |   |     |   |     186 |   |
| Administrative personnel compensation costs, including stock-based compensation                                                       |     |              |  1,592 |   |     |   |   1,434 |   |
| Rent and office costs                                                                                                                 |     |              |    279 |   |     |   |     365